VCA Stocks

Affimed Therapeutics, AG, a leading developer of next generation antibody therapeutics, today announced a second closing of Euro 5 million ($7.5 mm) to its Series B funding. This addition increases the total for the round to Euro 30 million in equity.  The money raised in this Series B financing will be used to fund Affimed’s proprietary therapeutic antibody programs. Based on its proprietary TandAb tetravalent antibody format the Company will focus specifically on the two clinical lead programs, a TandAb for the treatment of Hodgkin’s disease and another for the treatment of Non-Hodgkin’s Lymphoma (NHL). Affimed also plans to advance additional pre-clinical antibody programs for various other oncology and anti-inflammatory indications.